Totus Medicines

Totus Medicines has developed a proprietary high-throughput platform that leverages chemical biology and machine learning to discover covalent drugs targeting previously undruggable proteins. Their lead program targets the most mutated oncogene in cancer, with at least one candidate having entered clinical trials. The company claims unprecedented speed and breadth in discovering new therapeutics across the human genome, aiming for impact not only in oncology but also potentially cardiovascular and neurodegenerative diseases. Clinical results are not yet publicly detailed; however, their first-in-human trial marks a significant milestone.